SCHEMBL2684645

SCHEMBL2684645

CC(O)C(=O)Nc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
MAPT P10636 4/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
RXFP1 Q9HBX9 1/20 0.63
POLB P06746 1/20 0.59
GAA P10253 3/20 0.58
ATM Q13315 2/20 0.58
LMNA P02545 1/20 0.58
HSD17B10 Q99714 2/20 0.56
NAPRT Q6XQN6 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
HPGD P15428 2/20 0.55
HTT P42858 2/20 0.55
RAB9A P51151 2/20 0.55
HSP90AA1 P07900 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TAAR1 Q96RJ0 1/20 0.55
GPR55 Q9Y2T6 1/20 0.55
MME P08473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795034 1.00 ALDH1A1 (0.63) ALDH1A1MAPTMEN1KMT2ARXFP1
SCHEMBL18852431 0.84 ALDH1A1 (0.66) ALDH1A1MAPTMEN1KMT2ARXFP1
SCHEMBL19425986 0.84 ALDH1A1 (0.85) ALDH1A1MAPTMEN1KMT2ARXFP1
SCHEMBL9886 0.84 ALDH1A1 (0.85) ALDH1A1MAPTMEN1KMT2ARXFP1
SCHEMBL14546953 0.84 TAAR1 (0.57) ALDH1A1MAPTMEN1KMT2ARXFP1
SCHEMBL6864880 0.83 ALDH1A1 (0.63) ALDH1A1MAPTMEN1KMT2ARXFP1
Hydrochloric Acid SCHEMBL9145715 0.83 ALDH1A1 (0.81) ALDH1A1MAPTMEN1KMT2ARXFP1
Hydrochloric Acid SCHEMBL27725869 0.83 ALDH1A1 (0.81) ALDH1A1MAPTMEN1KMT2ARXFP1
SCHEMBL11659850 0.83 ALDH1A1 (0.81) ALDH1A1MAPTMEN1KMT2ARXFP1
SCHEMBL11882145 0.82 POLB (0.63) ALDH1A1MAPTMEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0261225-B1 LECTIN COMPLEX AND METHOD AND PROBE FOR MAKING SAME DANA FARBER CANCER INST INC (US) 1995-09-27 EP claimed
US-5395924-A Oligosaccharide or glycopeptide bound to lectin and conjugated with cell binding agent, improved targeting of cells for cytolysis DANA-FARBER CANCER INSTITUTE, INC. (US) 1995-03-07 US claimed
EP-0628315-A1 Lectin complex and probe and method for making same DANA-FARBER CANCER INSTITUTE, INC. (US) 1994-12-14 EP claimed
EP-0537259-A1 PROCESS FOR PRODUCING ENANTIOMERS OF 2-ARYL-ALKANOIC ACIDS NOVO NORDISK A/S (DK) 1993-04-21 EP claimed
EP-0261225-A4 LECTIN COMPLEX AND METHOD AND PROBE FOR MAKING SAME. DANA FARBER CANCER INST INC (US) 1989-10-27 EP claimed
EP-0261225-A1 LECTIN COMPLEX AND METHOD AND PROBE FOR MAKING SAME. DANA FARBER CANCER INST INC (US) 1988-03-30 EP claimed
WO-1987005515-A1 LECTIN COMPLEX AND METHOD AND PROBE FOR MAKING SAME DANA-FARBER CANCER INSTITUTE, INC. (US) 1987-09-24 WO claimed
EP-4651872-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Septerna, Inc. (US) 2025-11-26 EP disclosed
WO-2024155601-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS SEPTERNA, INC. (US) 2024-07-25 WO disclosed
CN-117623968-A Method for preparing N-substituted lactamide by catalyzing polylactic acid aminolysis with ionic liquid 中国科学院化学研究所 2024-03-01 CN disclosed
US-11603349-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD (AU) 2023-03-14 US disclosed
CN-107033102-B The synthetic method of mefenacet 江苏永凯化学有限公司 2019-07-05 CN disclosed
CN-107033102-A The synthetic method of mefenacet 江苏永凯化学有限公司 2017-08-11 CN disclosed
US-5239062-A Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity DANA-FARBER CANCER INSTITUTE, INC. (US) 1993-08-24 US disclosed
EP-0261225-A4 LECTIN COMPLEX AND METHOD AND PROBE FOR MAKING SAME. DANA FARBER CANCER INST INC (US) 1989-10-27 EP disclosed
EP-0261225-A1 LECTIN COMPLEX AND METHOD AND PROBE FOR MAKING SAME. DANA FARBER CANCER INST INC (US) 1988-03-30 EP disclosed
WO-1987005515-A1 LECTIN COMPLEX AND METHOD AND PROBE FOR MAKING SAME DANA-FARBER CANCER INSTITUTE, INC. (US) 1987-09-24 WO disclosed
EP-0177414-A1 Jodized triaminobenzene compounds, process for their preparation and their use in contrast products GUERBET S.A. (FR) 1986-04-09 EP disclosed
US-4276303-A SYSTEMIC FUNGICIDES FOR PHYTOPATHOGENIC FUNGI CIBA-GEIGY CORPORATION (US) 1981-06-30 US disclosed
US-4233308-A PHYTOPATHOGENIC FUNGICIDES CIBA-GEIGY CORPORATION (US) 1980-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603349-B2 Anti-fibrotic compounds TGFB1, SMAD3, TGFB2 ALDH1A1 1274/4885MAPT 3290/4885MEN1 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.